Huda Y. Zoghbi
Known title: DirectorCIK: 0001681643
Associated companies
Transaction History
| REGN | ▲ Buy | Option Exercise | 800 | $301K | 8/10/2026 | View on chart |
| REGN | ▼ Sell | Open Market | 800 | $640K | 8/10/2026 | View on chart |
| REGN | ▼ Sell | Open Market | 209 | $163K | 2/19/2026 | View on chart |
| REGN | ▲ Buy | Option Exercise | 1,638 | $617K | 2/19/2026 | View on chart |
| REGN | ▼ Sell | Open Market | 298 | $233K | 2/19/2026 | View on chart |
| REGN | ▼ Sell | Open Market | 56 | $44K | 2/19/2026 | View on chart |
| REGN | ▼ Sell | Open Market | 49 | $38K | 2/19/2026 | View on chart |
| REGN | ▼ Sell | Open Market | 50 | $39K | 2/19/2026 | View on chart |
| REGN | ▼ Sell | Open Market | 53 | $41K | 2/19/2026 | View on chart |
| REGN | ▼ Sell | Open Market | 208 | $162K | 2/19/2026 | View on chart |
| REGN | ▼ Sell | Open Market | 331 | $258K | 2/19/2026 | View on chart |
| REGN | ▼ Sell | Open Market | 160 | $126K | 2/19/2026 | View on chart |
| REGN | ▼ Sell | Open Market | 220 | $172K | 2/19/2026 | View on chart |
| REGN | ▼ Sell | Open Market | 4 | $3K | 2/19/2026 | View on chart |
| REGN | ▲ Buy | Grant | 155 | $0 | 1/2/2026 | View on chart |
| REGN | ▲ Buy | Grant | 166 | $0 | 1/2/2025 | View on chart |
| REGN | ▲ Buy | Option Exercise | 1,117 | $438K | 1/2/2024 | View on chart |
| REGN | ▼ Sell | Open Market | 1,117 | $1.0M | 1/2/2024 | View on chart |
| REGN | ▲ Buy | Grant | 135 | $0 | 1/2/2024 | View on chart |
| REGN | ▲ Buy | Option Exercise | 1,000 | $392K | 10/13/2023 | View on chart |
| REGN | ▼ Sell | Open Market | 1,000 | $850K | 10/13/2023 | View on chart |
| REGN | ▲ Buy | Grant | 165 | $0 | 1/3/2023 | View on chart |
| REGN | ▲ Buy | Option Exercise | 2,000 | $784K | 3/16/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 2,000 | $1.4M | 3/16/2022 | View on chart |
| REGN | ▲ Buy | Grant | 191 | $0 | 1/3/2022 | View on chart |
| REGN | ▲ Buy | Option Exercise | 998 | $391K | 9/14/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 998 | $649K | 9/14/2021 | View on chart |
| REGN | ▲ Buy | Option Exercise | 2 | $784 | 9/13/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 2 | $1K | 9/13/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Regeneron Gets EU Approval for Libtayo Dosing, UBS Upgrades Stock
Regeneron received a positive recommendation from the EU's CHMP for an updated Libtayo dosing regimen across all approved cancer types. This regulatory progress follows strong earnings and new Phase III data for a treatment for FOP. UBS recently upgraded the stock to Buy and raised its price target to $978, citing the company's potential value.
Regeneron Gets EU Approval for Libtayo Dosing, UBS Upgrades Stock. Regeneron received a positive recommendation from the EU's CHMP for an updated Libtayo dosing regimen across all approved cancer types. This regulatory progress follows strong earnings and new Phase III data for a treatment for FOP. UBS recently upgraded the stock to Buy and raised its price target to $978, citing the company's potential value.